autoimmune diseases

Merck breaks with Aqilion

Aqilion has completed the license and collaboration agreement with Merck for the joint development of the TAK1 program, targeting chronic inflammation....

Intervju

Aqilion's new program will be Best-in-Class

Aqilion develops treatments for diseases caused by chronic...

Intervju

Video

BioStock's article series on autoimmune disease: Finding the Common Denominator

BioStock's article series on autoimmune disease has so...

BioStock's article series on autoimmune disease: Drug Development for RA and MS

Therapies for autoimmune diseases are available but do...

BioStock's article series on autoimmune disease: The Science

Little is known about the exact causes of...

BioStock's article series on autoimmune disease: The Patients

Autoimmune diseases are on the rise, and no...